Skip to main content

Peer Review reports

From: AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

Original Submission
30 Sep 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
11 Jan 2022 Reviewed Reviewer Report - Moshe Elkabets
18 Jan 2022 Reviewed Reviewer Report
9 Feb 2022 Author responded Author comments - Deric Wheeler
Resubmission - Version 4
9 Feb 2022 Submitted Manuscript version 4
20 Feb 2022 Author responded Author comments - Deric Wheeler
Resubmission - Version 5
20 Feb 2022 Submitted Manuscript version 5
28 Feb 2022 Reviewed Reviewer Report - Moshe Elkabets
28 Feb 2022 Reviewed Reviewer Report
9 Mar 2022 Author responded Author comments - Deric Wheeler
Resubmission - Version 6
9 Mar 2022 Submitted Manuscript version 6
11 Mar 2022 Author responded Author comments - Deric Wheeler
Resubmission - Version 7
11 Mar 2022 Submitted Manuscript version 7
14 Mar 2022 Author responded Author comments - Deric Wheeler
Resubmission - Version 8
14 Mar 2022 Submitted Manuscript version 8
Publishing
7 Apr 2022 Editorially accepted
23 Apr 2022 Article published 10.1186/s12885-022-09511-6

You can find further information about peer review here.

Back to article page